Medtronic Diabetes Appoints Kate Cronin as CMO Amid Product Innovation Surge and IPO Preparations

On the morning of May 6, 2025, Medtronic announced the latest personnel appointment, with Kate Cronin set to serve as the Chief Marketing Officer of its diabetes business.

This is another key personnel arrangement by the department following the April appointment of former Dexcom executive Laura Endres as the head of the diabetes business in the Americas.

Cronin has many years of marketing experience.Cronin has been working at Moderna since 2021, responsible for promoting its COVID-19 vaccine.Last month, Kate Cronin had just left Moderna.

During his four-year tenure at Moderna, Cronin was responsible for building the company's brand and transitioning through the pandemic to an endemic phase.Adjusting Corporate Image During Epidemics.

Prior to this, she had worked at Ogilvy Health for 17 years, leaving the company as its global CEO.

Earlier today, the executive wrote on her LinkedIn page: "I am thrilled to join the Medtronic Diabetes leadership team as Chief Marketing Officer – Medtronic Diabetes is a global leader in diabetes care, dedicated to helping people forget about diabetes and live their best lives!"

"I am truly honored to embark on this adventurous journey with a company so committed to fulfilling its mission and a dynamic, empathetic team," she added.

Image source: LinkedIn

Following the Restructuring of the Executive Team, Medtronic's Diabetes Business Enters a Period of Explosive Product Innovation:

At the end of last month, this medical technology giant announced that it had received FDA approval to pair its Simplera Sync glucose sensor with the MiniMed 780G insulin pump.

At the end of last year, Medtronic received FDA approval to launch a companion app designed to work with the InPen digital insulin pen and Simplera sensor.

At the same time, Medtronic is also seeking approval for an integrated diabetes management system that combines Medtronic's insulin pump and drug delivery algorithm with Abbott's continuous glucose monitoring technology, and submitted an application to the FDA at the end of last month.